NEURON BIO, S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
| 2017 | Neol Biosolutions Seeks Investors | CI |
Business Summary
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
| Corporate Officer/Principal | 57 | - | |
| Corporate Secretary | 67 | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 19/05/19 | |
| Director/Board Member | 67 | - | |
| Director/Board Member | - | - | |
| Director/Board Member | - | - | |
| Director/Board Member | 75 | 24/19/24 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 15,611,366 | 13,569,480 ( 86.92 %) | 44,582 ( 0.2856 %) | 86.92 % |
Company contact information
Neuron Bio SA
P. T. S. Granada Calle Avenida de la Innovación No. 4
18016, Granada
+34 858 95 29 15
http://www.neuronbio.com
Group companies
| Name | Category and Sector |
|---|---|
Miscellaneous Commercial Services
|
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 5.19M | |
| +10.12% | 114B | |
| +12.46% | 107B | |
| -5.59% | 22.22B | |
| -0.67% | 21.28B | |
| -4.64% | 18.8B | |
| -6.84% | 17.51B | |
| -39.36% | 17.17B | |
| +6.73% | 14.14B | |
| +33.99% | 12.2B |
- Stock Market
- Equities
- NEU Stock
- Company Neuron Bio, S.A.
